Thursday 16 October, 2025
Objectives: Most point-of-care model-informed precision dosing (MIPD) software tools use maximum likelihood (maximum a posteriori MAP Bayesian) estimation to adjust…
Read moreAbstracts
Quantitative systems pharmacology modeling of thrombopoiesis and platelet life-cycle, and application for thrombocytopenia
Thursday 16 October, 2025
Objectives: Quantitative systems pharmacology (QSP) modeling provides mechanistic insight and contributes the comprehensive understanding of drug efficacy and effects of…
Read moreIntegrating a tumour Growth inhibition Model within a Physiologically-Based Pharmacokinetic Model to predict Erlotinib tumour concentrations in Mice
Thursday 16 October, 2025
Objectives: Erlotinib is a tyrosine kinase inhibitor that exerts its action intracellularly. Integrating a dynamic tumour growth inhibition model within…
Read moreImpact of OATP1B1 Polymorphism on Pravastatin Pharmacokinetics during Pregnancy; Physiologically Based Pharmacokinetic model Prediction
Thursday 16 October, 2025
Objectives: Pravastatin treatment has been reported to reduce the incidence of pre-eclampsia by 61% and premature birth by 45% [1]. Pravastatin…
Read moreApplication of translational physiologically based pharmacokinetic (PBPK) model for elucidating the complex disposition of ADCs: a case study with T-DM1
Thursday 16 October, 2025
Objectives: Antibody drug conjugates (ADCs) are a class of targeted cancer therapies which aim to widen the therapeutic index by combining…
Read moreA Physiologically Based Pharmacokinetic model to explore the blood-milk barrier in lactating species: case study with oxytetracycline
Thursday 16 October, 2025
Objectives: The presence of antibiotic residues in the milk of farm animals can have an impact on human health, in…
Read morePopulation pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations
Thursday 16 October, 2025
Introduction/Objectives: Macozinone (PBTZ-169) is a new benzothiazinone anti-tuberculosis drug candidate that selectively and irreversibly inhibits the DprE1 enzyme of Mycobacterium…
Read moreAn integrative translational framework for in vitro modelling for macozinone to support prediction of early human anti-tubercular efficacy
Thursday 16 October, 2025
Introduction/Objectives: Macozinone (PBTZ169) is a new drug candidate with novel mechanism of action for treatment of tuberculosis. This compound has…
Read moreTranslational Model-Informed Selection of Tuberculosis Drug Combination Regimens for Early Clinical Development
Thursday 16 October, 2025
Objectives: There is still a gap between pre-clinical and clinical phase in tuberculosis (TB) drug development. New innovative tools are needed…
Read moreTranslational PK and PKPD modelling for the analysis of preclinical in-vitro and in-vivo studies to predict efficacious human dose of apramycin
Thursday 16 October, 2025
Objectives: Predictions of human dose for antibiotics are commonly based on 24h response in mouse infection models, ignoring the dynamics…
Read more